Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab in High-risk Thyroid Cancers
NCT05852223Phase 2Recruiting
- Sponsor
- Istituti Clinici Scientifici Maugeri
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in differentiated thyroid cancer (DTC), sponsored by Istituti Clinici Scientifici Maugeri. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT05852223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05852223.